Welcome to
Издательство Атмосфера

· Журналы
· Книги
· О проекте

·Электронные версии книг издательства “Атмосфера” поступили в продажу

Издательство “Атмосфера” идет в ногу со временем и открывает на своем сайте раздел электронных версий своих книг. Теперь вы можете приобрести не только традиционную бумажную книгу в картонном переплете, но и .pdf-файл, снабженный гиперссылками на каждую главу издания. В электронной версии проще отыскать рисунок и таблицу. Чтобы обратиться к ним, достаточно нажать на ссылку на каждый из них. Исчезла зависимость от тиража – вы можете приобрести даже те бестселлеры, тираж которых уже разошелся, такие как “Саркоидоз” или “Заболевания органов дыхания при беременности”. Упростилось получение вами книг – в течение двух рабочих дней после оплаты требуемые файлы придут на ваш e-mail. Ну и наконец, цена – электронные версии наших книг гораздо дешевле, чем бумажные издания. Заказывайте электронные версии книг издательства “Атмосфера” на сайте, а также по телефону: (495) 730-63-51 и по e-mail: atm-press2012@yandex.ru


ИНТЕРНЕТ-МАГАЗИН
Издательство Атмосфера


Телефон издательства

  
Практическая пульмонология (ранее – "Атмосфера. Пульмонология и аллергология"): ISSN 2409-756X (Online), ISSN 2409-6636 (Print)
2022 / N 1

Практическое применение препарата бенрализумаб
Н.П. Княжеская, Э.Х. Анаев, А.А. Камелева, Е.В. Сафошкина, А.С. Белевский

References

1. Global Initiative for Asthma. Global strategy for asthma management and prevention. Revised 2014. Available from: https://ginasthma.org/wp-content/uploads/2019/01/2014-GINA.pdf Accessed 2022 Oct 10.
2. Global Initiative for Asthma. Global strategy for asthma management and prevention. Updated 2020. Available from: https://ginasthma.org/wp-content/uploads/2020/06/GINA-2020-report_20_06_04-1-wms.pdf Accessed 2022 Oct 10.
3. Global Initiative for Asthma. Global strategy for asthma management and prevention. Updated 2022. Available from: https://ginasthma.org/wp-content/uploads/2022/07/GINA-Main-Report-2022-FINAL-22-07-01-WMS.pdf Accessed 2022 Oct 10.
4. Фассахов Р.С., Богоутдинова О.Е., Владимирова Д.И. Сте­рои­дозависимая бронхиальная астма. Атмосфера. Пульмонология и аллергология 2002;1:11-4.
5. Pavord ID. Oral corticosteroid-dependent asthma: current knowledge and future needs. Current Opinion in Pulmonary Medicine 2019 Jan;25(1):51-8.
6. Shaaban R, Zureik M, Soussan D, Neukirch C, Heinrich J, Sunyer J, Wjst M, Cerveri I, Pin I, Bousquet J, Jarvis D, Burney PG, Neukirch F, Leynaert B. Rhinitis and onset of asthma: a longitudinal population-based study. The Lancet 2008 Sep;372(9643):1049-57.
7. Fokkens W, Lund V, Mullol J; European Position Paper on Rhinosinusitis and Nasal Polyps group. European position paper on rhinosinusitis and nasal polyps 2007. Rhinology. Supplement 2007;20:1-136.
8. Brożek JL, Bousquet J, Agache I, Agarwal A, Bachert C, Bosnic-Anticevich S, Brignardello-Petersen R, Canonica GW, Casale T, Chavannes NH, Correia de Sousa J, Cruz AA, Cuello-Garcia CA, Demoly P, Dykewicz M, Etxeandia-Ikobaltzeta I, Florez ID, Fokkens W, Fonseca J, Hellings PW, Klimek L, Kowalski S, Kuna P, Laisaar KT, Larenas-Linnemann DE, Lødrup Carlsen KC, Manning PJ, Meltzer E, Mullol J, Muraro A, O’Hehir R, Ohta K, Panzner P, Papadopoulos N, Park HS, Passalacqua G, Pawankar R, Price D, Riva JJ, Roldán Y, Ryan D, Sadeghirad B, Samolinski B, Schmid-Grendelmeier P, Sheikh A, Togias A, Valero A, Valiulis A, Valovirta E, Ventresca M, Wallace D, Waserman S, Wickman M, Wiercioch W, Yepes-Nuñez JJ, Zhang L, Zhang Y, Zidarn M, Zuberbier T, Schünemann HJ. Allergic Rhinitis and its Impact on Asthma (ARIA) guideline – 2016 revision. The Journal of Allergy and Clinical Immunology 2017 Oct;140(4):950-8.
9. Jarjour NN, Erzurum SC, Bleecker ER, Calhoun WJ, Castro M, Comhair SA, Chung KF, Curran-Everett D, Dweik RA, Fain SB, Fitzpatrick AM, Gaston BM, Israel E, Hastie A, Hoffman EA, Holguin F, Levy BD, Meyers DA, Moore WC, Peters SP, Sorkness RL, Teague WG, Wenzel SE, Busse WW; NHLBI Severe Asthma Research Program (SARP). Severe asthma: lessons learned from the National Heart, Lung, and Blood Institute Severe Asthma Research Program. American Journal of Respiratory and Critical Care Medicine 2012 Feb;185(4):356-62.
10. Barnes PJ. Scientific rationale for inhaled combination therapy with long-acting b2-agonists and corticosteroids. The European Respiratory Journal 2002 Jan;19(1):182-91.
11. O’Byrne PM, Bisgaard H, Godard PP, Pistolesi M, Palmqvist M, Zhu YJ, Ekstrom T, Bateman ED. Budesonide/formoterol combination therapy as both maintenance and reliever medication in asthma. American Journal of Respiratory and Critical Care Medicine 2005 Jan;171(2):129-36.
12. Holguin F, Cardet JC, Chung KF, Diver S, Ferreira DS, Fitzpatrick A, Gaga M, Kellermeyer L, Khurana S, Knight S, McDo­nald VM, Morgan RL, Ortega VE, Rigau D, Subbarao P, Tonia T, Adcock IM, Bleecker ER, Brightling C, Boulet LP, Cabana M, Castro M, Chanez P, Custovic A, Djukanovic R, Frey U, Frankemölle B, Gibson P, Hamerlijnck D, Jarjour N, Konno S, Shen H, Vitary C, Bush A. Management of severe asthma: a European Respiratory Society/American Thoracic Society guideline. The European Respiratory Journal 2020 Jan;55(1):1900588.
13. Price D, Fletcher M, van der Molen T. Asthma control and management in 8,000 European patients: the REcognise Asthma and LInk to Symptoms and Experience (REALISE) survey. NPJ Primary Care Respiratory Medicine 2014 Jun;24:14009.
14. Chung KF. Defining phenotypes in asthma: a step towards personalized medicine. Drugs 2014 May;74(7):719-28.
15. Fajt ML, Wenzel SE. Asthma phenotypes and the use of biologic medications in asthma and allergic disease: the next steps toward personalized care. The Journal of Allergy and Clinical Immunology 2015 Feb;135(2):299-310; quiz 311.
16. Dahlén SE. Asthma phenotyping: noninvasive biomarkers suitable for bedside science are the next step to implement precision medicine. Journal of Internal Medicine 2016 Feb;279(2):205-7.
17. Matucci A, Maggi E, Vultaggio A. Eosinophils, the IL-5/IL-5Ra axis, and the biologic effects of benralizumab in severe asthma. Respiratory Medicine 2019 Nov-Dec;160:105819.
18. Kolbeck R, Kozhich A, Koike M, Peng L, Andersson CK, Damschroder MM, Reed JL, Woods R, Dall’acqua WW, Stephens GL, Erjefalt JS, Bjermer L, Humbles AA, Gossage D, Wu H, Kiener PA, Spitalny GL, Mackay CR, Molfino NA, Coyle AJ. MEDI-563, a humanized anti-IL-5 receptor a mAb with enhanced antibody-dependent cell-mediated cytotoxicity function. The Journal of Allergy and Clinical Immunology 2010 Jun;125(6):1344-53.e2.
19. Pham TH, Damera G, Newbold P, Ranade K. Reductions in eosi­nophil biomarkers by benralizumab in patients with asthma. Respiratory Medicine 2016 Feb;111:21-9.
20. Bleecker ER, FitzGerald JM, Chanez P, Papi A, Weinstein SF, Barker P, Sproule S, Gilmartin G, Aurivillius M, Werkström V, Goldman M; SIROCCO study investigators. Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting b2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial. The Lancet 2016 Oct;388(10056):2115-27.
21. FitzGerald JM, Bleecker ER, Nair P, Korn S, Ohta K, Lommatzsch M, Ferguson GT, Busse WW, Barker P, Sproule S, Gilmartin G, Werkström V, Aurivillius M, Goldman M; CALIMA study investigators. Benralizumab, an anti-interleukin-5 receptor a monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial. The Lancet 2016 Oct;388(10056):2128-41.
22. Busse WW, Bleecker ER, FitzGerald JM, Ferguson GT, Barker P, Sproule S, Olsson RF, Martin UJ, Goldman M; BORA study investigators. Long-term safety of benralizumab in patients with severe, uncontrolled asthma: 1-year results from the BORA phase 3 extension trial. The Lancet. Respiratory Medicine 2019 Jan;7(1):46-59.
23. Jackson DJ, Korn S, Mathur SK, Barker P, Meka VG, Martin UJ, Zangrilli JG. Safety of eosinophil-depleting therapy for severe, eosinophilic asthma: focus on benralizumab. Drug Safety 2020 May;43(5):409-25.
24. Nair P, Wenzel S, Rabe KF, Bourdin A, Lugogo NL, Kuna P, Barker P, Sproule S, Ponnarambil S, Goldman M; ZONDA Trial Investigators. Oral glucocorticoid-sparing effect of benralizumab in severe asthma. The New England Journal of Medicine 2017 Jun;376(25):2448-58.
25. Menzies-Gow A, Corren J, Bel EH, Maspero J, Heaney LG, Gurnell M, Wessman P, Martin UJ, Siddiqui S, Garcia Gil E. Corticosteroid tapering with benralizumab treatment for eosi­nophilic asthma: PONENTE Trial. ERJ Open Research 2019 Sep;5(3):00009-2019.
26. ClinicalTrials.gov. A safety extension study with benralizumab for asthmatic adults on inhaled corticosteroid plus long-acting b2 agonist (MELTEMI). Available from: https://clinicaltrials.gov/ct2/show/NCT02808819?term= MELTEMI+benralizumab&draw=2&rank=1 Accessed 2022 Oct 10.
  

[ Содержание выпуска N 1 | Выпуски журнала | Список журналов ]